Aug. 25 at 1:52 AM
$ABEO TIP RANKS ABEO HIGHLIGHTS:
FDA Approval of ZEVASKYN
ZEVASKYN was approved by the FDA in April 2025, marking a significant milestone for Abeona Therapeutics. It is the first and only autologous cell-based gene therapy for RDEB, offering meaningful healing for wounds associated with the condition.
Strong Initial Demand for ZEVASKYN
Within the first three months post-approval, over 50 patients have been identified as candidates for ZEVASKYN, with referrals from both QTCs and other centers.
Positive Reimbursement Trends
ZEVASKYN has achieved positive coverage with multiple national and regional payers, including UnitedHealthcare, and enjoys a 100% prior authorization success rate.
Financial Strength and Profitability Outlook
Abeona reported
$225.9 million in cash and anticipates achieving company-wide profitability by early 2026, supported by ZEVASKYN sales.
Community Engagement and Positive Patient Feedback
ls reporting durable wound healing lasting several years.
